Reading view

SoK: DARPA's AI Cyber Challenge (AIxCC): Competition Design, Architectures, and Lessons Learned

By: Cen Zhang · Younggi Park · Fabian Fleischer · Yu-Fu Fu · Jiho Kim · Dongkwan Kim · Youngjoon Kim · Qingxiao Xu · Andrew Chin · Ze Sheng · Hanqing Zhao · Michael Pelican · David J. Musliner · Jeff Huang · Jon Silliman · Mikel Mcdaniel · Jefferson Casavant · Isaac Goldthwaite · Nicholas Vidovich · Matthew Lehman · Taesoo Kim

26 May 2026 at 12:00

arXiv:2602.07666v3 Announce Type: replace-cross Abstract: DARPA's AI Cyber Challenge (AIxCC, 2023--2025) is the largest competition to date for building fully autonomous cyber reasoning systems (CRSs) that leverage recent advances in AI -- particularly large language models (LLMs) -- to discover and remediate vulnerabilities in real-world open-source software. This paper presents the first systematic analysis of AIxCC. Drawing on design documents, source code, execution traces, and discussions with organizers and competing teams, we examine the competition's structure and key design decisions, characterize the architectural approaches of finalist CRSs, and analyze competition results beyond the final scoreboard. Our analysis reveals the factors that truly drove CRS performance, identifies genuine technical advances achieved by teams, and exposes limitations that remain open for future research. We conclude with lessons for organizing future competitions and broader insights toward deploying autonomous CRSs in practice.

Pulmonary-Intestinal Axis: Shared Genetic Basis and Mediating Factors Identified Through Multi-Omics Analysis

Omics In Lung

By: Zhenzhu Zhang · Haoyue Liu · Yihang Su · Chengwen Wang · Wei Wang · Yinglin Li · Xiaobao Zhang · Chenguang Gao · Xue Tian · Chunqing Zhao

14 April 2026 at 18:00

Int J Chron Obstruct Pulmon Dis. 2026 Apr 7;21:561645. doi: 10.2147/COPD.S561645. eCollection 2026.

ABSTRACT

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a systemic condition with comorbidities beyond the lung (eg, cardiovascular and metabolic disorders), and gastrointestinal (GI) disorders are also common. The shared genetic basis of COPD-GI comorbidity and its mediating factors remain unclear. We hypothesized that COPD and GI diseases share pleiotropic genetic architecture implicating lipid-metabolic pathways, with smoking mediating part of the association.

METHODS: We analyzed publicly available European-ancestry GWAS summary statistics for COPD (Global Biobank Meta-analysis Initiative), 15 GI diseases (FinnGen), and smoking phenotypes (UK Biobank). Genetic correlation was estimated using linkage disequilibrium score regression (LDSC) and high-definition likelihood (HDL). Multi-trait analysis of GWAS (MTAG) boosted COPD discovery by leveraging genetically correlated GI traits. We integrated locus-to-gene mapping with multi-tissue expression quantitative trait loci (eQTL) and plasma protein quantitative trait loci (pQTL) evidence to prioritize shared loci, genes, and proteins. Bidirectional two-sample Mendelian randomization (MR) tested causal directions, and two-step mediation MR evaluated smoking.

RESULTS: COPD showed significant genetic correlation with nine GI diseases. We identified six comorbidity-associated loci (three with CADD > 12.37) and 13 unique candidate pleiotropic genes; APOE was supported by proteomic evidence. Enrichment analyses highlighted lipid-metabolism pathways. MR suggested COPD increases risk of gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), acute appendicitis, and gastric ulcer, while diverticular disease showed reverse causality toward COPD. Smoking partially mediated the COPD effect on GERD, acute appendicitis, and gastric ulcer.

CONCLUSION: COPD and multiple GI disorders share a distributed pleiotropic genetic basis within the broader systemic comorbidity spectrum of COPD. Multi-omics evidence supports a genomic pulmonary-intestinal axis in which lipid metabolism and smoking-related mechanisms contribute to COPD and GI comorbidity, providing targets for risk stratification and potential intervention.

PMID:41978582 | PMC:PMC13070119 | DOI:10.2147/COPD.S561645